{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:18:28Z","timestamp":1790536708837,"version":"4.1.0"},"reference-count":80,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.2967\/jnumed.119.228320","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T19:25:54Z","timestamp":1567538754000},"page":"1350-1358","source":"Crossref","is-referenced-by-count":70,"title":["Multimodality Imaging of Prostate Cancer"],"prefix":"10.2967","volume":"60","author":[{"given":"Soleen","family":"Ghafoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto H.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"2021051712135185000_60.10.1350.1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.urolonc.2018.05.008","article-title":"Intratumor heterogeneity in prostate cancer","volume":"36","author":"Yadav","year":"2018","journal-title":"Urol Oncol."},{"key":"2021051712135185000_60.10.1350.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.10.055"},{"key":"2021051712135185000_60.10.1350.3","doi-asserted-by":"crossref","unstructured":"Turkbey B Rosenkrantz AB Haider MA . Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. European Urology.","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"2021051712135185000_60.10.1350.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.07.013"},{"key":"2021051712135185000_60.10.1350.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.052"},{"key":"2021051712135185000_60.10.1350.6","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1016\/S1470-2045(18)30604-1","article-title":"Consensus on molecular imaging and theranostics in prostate cancer","volume":"19","author":"Fanti","year":"2018","journal-title":"Lancet Oncol."},{"key":"2021051712135185000_60.10.1350.7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","article-title":"METastasis Reporting and Data System for Prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer","volume":"71","author":"Padhani","year":"2017","journal-title":"Eur Urol."},{"key":"2021051712135185000_60.10.1350.8","doi-asserted-by":"crossref","unstructured":"Metser U Chua SS Ho B . The contribution of multiparametric pelvic & whole body MR to interpretation of 18F-fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET\/CT in patients with biochemical failure following radical prostatectomy. J Nucl Med. March 22, 2019 [Epub ahead of print].","DOI":"10.2967\/jnumed.118.225185"},{"key":"2021051712135185000_60.10.1350.9","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1007\/s00259-018-4058-4","article-title":"Prospective comparison of 68Ga-PSMA PET\/CT, 18F-sodium fluoride PET\/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer","volume":"45","author":"Zacho","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712135185000_60.10.1350.10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.euf.2016.06.018","article-title":"Rationale for modernising imaging in advanced prostate cancer","volume":"3","author":"Padhani","year":"2017","journal-title":"Eur Urol Focus."},{"issue":"4","key":"2021051712135185000_60.10.1350.11","first-page":"14N","article-title":"Appropriate use criteria for bone scintigraphy in prostate and breast cancer: summary and excerpts","volume":"58","author":"Donohoe","year":"2017","journal-title":"J Nucl Med."},{"key":"2021051712135185000_60.10.1350.12","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2016150059"},{"key":"2021051712135185000_60.10.1350.13","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2016.07.004"},{"key":"2021051712135185000_60.10.1350.14","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13130625"},{"key":"2021051712135185000_60.10.1350.15","first-page":"1077","article-title":"Is 18F-FDG PET\/CT a useful tool in prostate cancer? [abstract]","volume":"58","author":"Shen","year":"2017","journal-title":"J Nucl Med."},{"key":"2021051712135185000_60.10.1350.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.082263"},{"key":"2021051712135185000_60.10.1350.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.189183"},{"key":"2021051712135185000_60.10.1350.18","doi-asserted-by":"publisher","DOI":"10.7150\/thno.4008"},{"key":"2021051712135185000_60.10.1350.19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2478\/v10019-010-0050-8","article-title":"Role of 18F-choline PET\/CT in evaluation of patients with prostate carcinoma","volume":"45","author":"Hodolic","year":"2011","journal-title":"Radiol Oncol."},{"key":"2021051712135185000_60.10.1350.20","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.11102023"},{"key":"2021051712135185000_60.10.1350.21","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S"},{"key":"2021051712135185000_60.10.1350.22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3348\/kjr.2018.19.5.819","article-title":"Prostate-specific membrane antigen PET imaging in prostate cancer: opportunities and challenges","volume":"19","author":"Oh","year":"2018","journal-title":"Korean J Radiol."},{"key":"2021051712135185000_60.10.1350.23","doi-asserted-by":"crossref","unstructured":"Kesler M Levine C Hershkovitz D . 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: a prospective pilot study. J Nucl Med. July 12, 2018 [Epub ahead of print].","DOI":"10.2967\/jnumed.118.214833"},{"key":"2021051712135185000_60.10.1350.24","doi-asserted-by":"crossref","first-page":"9867","DOI":"10.18632\/oncotarget.23984","article-title":"Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid","volume":"9","author":"Heitk\u00f6tter","year":"2018","journal-title":"Oncotarget."},{"key":"2021051712135185000_60.10.1350.25","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2021051712135185000_60.10.1350.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.212233"},{"key":"2021051712135185000_60.10.1350.27","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318282635a"},{"key":"2021051712135185000_60.10.1350.28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.euf.2016.11.012","article-title":"The molecular evolution of castration-resistant prostate cancer","volume":"2","author":"Ceder","year":"2016","journal-title":"Eur Urol Focus."},{"key":"2021051712135185000_60.10.1350.29","first-page":"366","article-title":"Tumor localization of 16\u03b2-18F-fluoro-5\u03b1-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer","volume":"45","author":"Larson","year":"2004","journal-title":"J Nucl Med."},{"key":"2021051712135185000_60.10.1350.30","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.2967\/jnumed.117.206490","article-title":"Reproducibility and repeatability of semiquantitative 18F-fluorodihydrotestosterone uptake metrics in castration-resistant prostate cancer metastases: a prospective multicenter study","volume":"59","author":"Vargas","year":"2018","journal-title":"J Nucl Med."},{"key":"2021051712135185000_60.10.1350.31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol."},{"key":"2021051712135185000_60.10.1350.32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1148\/radiol.2018172232","article-title":"Gallium 68 PSMA-11 PET\/MR imaging in patients with intermediate- or high-risk prostate cancer","volume":"288","author":"Park","year":"2018","journal-title":"Radiology."},{"key":"2021051712135185000_60.10.1350.33","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1148\/radiol.2018180788","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET\/MRI compared with multiparametric MRI in the detection of prostate cancer","volume":"289","author":"Hicks","year":"2018","journal-title":"Radiology."},{"key":"2021051712135185000_60.10.1350.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1"},{"key":"2021051712135185000_60.10.1350.35","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med."},{"key":"2021051712135185000_60.10.1350.36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eururo.2017.02.026","article-title":"What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel","volume":"72","author":"Moldovan","year":"2017","journal-title":"Eur Urol."},{"key":"2021051712135185000_60.10.1350.37","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00261-018-1823-6","article-title":"Characteristics of missed prostate cancer lesions on 3T multiparametric-MRI in 518 patients: based on PI-RADSv2 and using whole-mount histopathology reference","volume":"44","author":"Mohammadian Bajgiran","year":"2019","journal-title":"Abdom Radiol (NY)."},{"key":"2021051712135185000_60.10.1350.38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1148\/radiol.2017152877","article-title":"What are we missing? False-negative cancers at multiparametric MR imaging of the prostate","volume":"286","author":"Borofsky","year":"2018","journal-title":"Radiology."},{"key":"2021051712135185000_60.10.1350.39","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2383050657"},{"key":"2021051712135185000_60.10.1350.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.029"},{"key":"2021051712135185000_60.10.1350.41","unstructured":"M\u00fchlematter UJ Becker KSA M\u00fcller J . Detection of extracapsular extension in high risk prostate cancer patients: multiparametric MRI vs. 68Ga-PSMA-11 PET\/MRI. Paper presented at: 2019 European Congress of Radiology; February 28, 2019; Vienna, Austria."},{"key":"2021051712135185000_60.10.1350.42","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182556dcd"},{"key":"2021051712135185000_60.10.1350.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.10.057"},{"key":"2021051712135185000_60.10.1350.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.10.044"},{"key":"2021051712135185000_60.10.1350.45","first-page":"1509","article-title":"Current concepts in lymph node imaging","volume":"45","author":"Torabi","year":"2004","journal-title":"J Nucl Med."},{"key":"2021051712135185000_60.10.1350.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2007.05.022"},{"key":"2021051712135185000_60.10.1350.47","doi-asserted-by":"crossref","first-page":"W95","DOI":"10.2214\/AJR.17.18481","article-title":"The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: an updated systematic review and diagnostic meta-analysis","volume":"210","author":"Woo","year":"2018","journal-title":"AJR."},{"key":"2021051712135185000_60.10.1350.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.09.039"},{"key":"2021051712135185000_60.10.1350.49","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1007\/s00330-017-5213-1","article-title":"18F-fluciclovine PET\/MRI for preoperative lymph node staging in high-risk prostate cancer patients","volume":"28","author":"Seln\u00e6s","year":"2018","journal-title":"Eur Radiol."},{"key":"2021051712135185000_60.10.1350.50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bju.14374","article-title":"A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET\/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol","volume":"122","author":"Hofman","year":"2018","journal-title":"BJU Int."},{"key":"2021051712135185000_60.10.1350.51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0768"},{"key":"2021051712135185000_60.10.1350.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.12.025"},{"key":"2021051712135185000_60.10.1350.53","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3106-6"},{"key":"2021051712135185000_60.10.1350.54","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamaoncol.2018.1093","article-title":"Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer: a secondary analysis of a randomized clinical trial","volume":"4","author":"Armstrong","year":"2018","journal-title":"JAMA Oncol."},{"key":"2021051712135185000_60.10.1350.55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2021051712135185000_60.10.1350.56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"2021051712135185000_60.10.1350.57","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","article-title":"Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer","volume":"43","author":"Pyka","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712135185000_60.10.1350.58","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol."},{"key":"2021051712135185000_60.10.1350.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.045"},{"key":"2021051712135185000_60.10.1350.60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/2156-7514.181494","article-title":"Multiparametric magnetic resonance imaging of recurrent prostate cancer","volume":"6","author":"Oppenheimer","year":"2016","journal-title":"J Clin Imaging Sci."},{"key":"2021051712135185000_60.10.1350.61","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13122149"},{"key":"2021051712135185000_60.10.1350.62","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2130-6"},{"key":"2021051712135185000_60.10.1350.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2012.11.010"},{"key":"2021051712135185000_60.10.1350.64","unstructured":"Sandgren K Westerlinck P Jonsson JH . Imaging for the detection of locoregional recurrences in biochemical progression after radical prostatectomy: a systematic review. Eur Urol Focus. November 11, 2017 [Epub ahead of print]."},{"key":"2021051712135185000_60.10.1350.65","first-page":"3770","article-title":"Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment","volume":"20","author":"Barchetti","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"2021051712135185000_60.10.1350.66","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2967\/jnumed.118.221564","article-title":"68Ga-PSMA-11 PET\/MR detects local recurrence occult on mpMRI in prostate cancer patients after HIFU","volume":"60","author":"Burger","year":"2019","journal-title":"J Nucl Med."},{"key":"2021051712135185000_60.10.1350.67","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","article-title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI","volume":"44","author":"Freitag","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712135185000_60.10.1350.68","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2525-5"},{"key":"2021051712135185000_60.10.1350.69","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JU.0000000000000198","article-title":"Imaging of prostate specific membrane antigen targeted radiotracers for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis","volume":"202","author":"Tan","year":"2019","journal-title":"J Urol."},{"key":"2021051712135185000_60.10.1350.70","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1038\/s41598-018-22594-1","article-title":"PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis","volume":"8","author":"Bravaccini","year":"2018","journal-title":"Sci Rep."},{"key":"2021051712135185000_60.10.1350.71","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.juro.2018.08.050","article-title":"The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial","volume":"201","author":"Andriole","year":"2019","journal-title":"J Urol."},{"key":"2021051712135185000_60.10.1350.72","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.220541"},{"key":"2021051712135185000_60.10.1350.73","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol."},{"key":"2021051712135185000_60.10.1350.74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2019.37.7_suppl.15","article-title":"Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET\/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy [abstract]","volume":"37","author":"Calais","year":"2019","journal-title":"J Clin Oncol."},{"key":"2021051712135185000_60.10.1350.75","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170134"},{"key":"2021051712135185000_60.10.1350.76","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamaoncol.2017.3588","article-title":"Positron emission tomography\/computed tomography\u2013based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer","volume":"4","author":"Fox","year":"2018","journal-title":"JAMA Oncol."},{"key":"2021051712135185000_60.10.1350.77","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191023"},{"key":"2021051712135185000_60.10.1350.78","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183194"},{"key":"2021051712135185000_60.10.1350.79","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"2021051712135185000_60.10.1350.80","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","article-title":"Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review","volume":"45","author":"von Eyben","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.119.228320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T10:15:57Z","timestamp":1664273757000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.119.228320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":80,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,1]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.2967\/jnumed.119.228320"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.119.228320","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}